VAUGHAN, Ontario, July 11, 2018 /PRNewswire/ —
The study is designed to evaluate the efficacy of CannTrust’s Cannabidiol Oil Capsules in slowing Amyotrophic Lateral Sclerosis (ALS) progressionÂ
CannTrust Holdings Inc. (“CannTrust” or the “Company”) (TSX: TRST), one of Canada’s leading licensed producers of medical cannabis, announced today that it has partnered with Australia’s Gold Coast University Hospital (“Gold Coast“) to conduct a randomized, double-blind, placebo-controlled clinical trial to determine the efficacy of CannTrust cannabidiol (CBD) oil capsules in slowing the disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND). Patient safety and tolerability will also be assessed. The study has received Research Ethics Board approval and Australian Therapeutic Good Administration Acknowledgement for the study drug.
The six-month study will be led by Gold Coast Neurologist, Dr. Arman Sabet, MD. Gold Coast is one of Australia’s leading tertiary referral institutions for